Johnson & Johnson: positive opinion for guselkumab in Europe
(CercleFinance.com) - Janssen-Cilag, a Johnson & Johnson division, has said that Europe's CHMP has issued a positive opinion recommending marketing authorisation for the use of guselkumab in the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
A final decision from the European Commission is expected later this year.
In the US, Janssen already received FDA approval of guselkumab for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in July.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
A final decision from the European Commission is expected later this year.
In the US, Janssen already received FDA approval of guselkumab for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in July.
Copyright (c) 2017 CercleFinance.com. All rights reserved.